<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-BQVDYG6H/4c7aa15d-44c1-47fd-aea1-fb383d231637/PDF"><dcterms:extent>453 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-BQVDYG6H/ce6aeb00-238e-4525-bf00-8f0c663064ce/TEXT"><dcterms:extent>26 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-BQVDYG6H"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2015</dcterms:issued><dc:creator>Budihna, Marjan</dc:creator><dc:creator>Gale, Nina</dc:creator><dc:creator>Lešničar, Hotimir</dc:creator><dc:creator>Strojan, Primož</dc:creator><dc:creator>Šmid, Alojz</dc:creator><dc:creator>Šoba, Erika</dc:creator><dc:creator>Zakotnik, Branko</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:49</dc:format><dc:format xml:lang="sl">str. 365-370, IV</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:2215035</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-BQVDYG6H</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">oropharynx</dc:subject><dc:subject xml:lang="en">radiochemotherapy</dc:subject><dc:subject xml:lang="sl">radiokemoterapija</dc:subject><dc:subject xml:lang="en">tumor markers</dc:subject><dc:subject xml:lang="sl">tumorji</dc:subject><dc:subject xml:lang="sl">tumorski označevalci</dc:subject><dc:subject xml:lang="sl">ustno žrelo</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy|</dc:title><dc:description xml:lang="sl">The aim of the study was to investigate how the expression of tumor markers p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31 influenced the outcome of advanced inoperable oropharyngeal carcinoma patients, treated with concomitant radiochemotherapy. Patients and methods. The pretreatment biopsy specimens of 74 consecutive patients with inoperable stage IV oropharyngeal squamous cell carcinoma treated with concomitant radiochemotherapy were in retrospective study processed by immunochemistry for p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31. Disease-free survival (DFS) was assessed according to the expression of tumor markers. Results. Patients with a high expression of p21 (%10%), p27 (&gt;50%), Ki-67 (&gt;50%), CD31 (&gt;130 vessels/mm2) and low expression of p53 (&lt;10%), cyclin D1 (&lt;10%) and EGFR (&lt;10%) (favorable levels - FL) had better DFS than patients with a low expression of p21 (&lt;10%), p27 (%50%), Ki-67 (%50%), CD31 (&lt;130 vessels/mm2) and high expression of p53 (%10%), cyclin D1 (%10%) and EGFR (%10%) (unfavorable levels - UL). However, statistical significance in survival between FL and UL was achieved only for p27 and cyclin D1. DFS significantly decreased with an increasing number of markers with an unfavorable level per tumor (1%4 vs. 5%7) (78% vs. 32%, respectively; p = 0.004). The number of markers per tumor with UL of expression retained prognostic significance also in multivariate analysis. Conclusions. Statistical significance in survival between FL and UL emerged only for p27 and cyclin D1. The number of markers per tumor with UL of expression was an independent prognostic factor for an adverse outcome </dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-BQVDYG6H"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-BQVDYG6H" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-BQVDYG6H/4c7aa15d-44c1-47fd-aea1-fb383d231637/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-BQVDYG6H/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-BQVDYG6H" /></ore:Aggregation></rdf:RDF>